Oral Session 1-7C Multiple Myeloma: Multicenter Clinical Trials

[OS1-7C-2] Elotuzumab plus len/dex for NDMM: efficacy/safety and sSLAMF7 analysis in Japanese patients

Kensuke Ohta^1,2, Mitsuo Hori³, Hiroshi Handa⁴, Gen Kinoshita⁵, Suresh Shelat⁶, Masafumi Miyoshi⁵, Naoki Takezako⁷, Kohmei Kubo⁸ (1.Department of Hematology, Osaka Saiseikai Nakatsu Hospital, Osaka, Japan, 2.Hematology Ohta Clinica, Shinsaibashi, Osaka, Japan, 3.Department of Hematology, Ibaraki Prefectural Central Hospital, Kasama, Japan, 4.Department of Hematology, Gunma University Hospital, Maebashi, Japan, 5.Bristol-Myers Squibb K.K., Tokyo, Japan, 6.Bristol-Myers Squibb, Princeton, NJ, USA, 7.National Hospital Organization Disaster Medical Center, Tokyo, Japan, 8.Department of Hematology, Aomori Prefectural Central Hospital, Aomori, Japan)